Pfizer's CEO warns that China's meticulously executed national plan for pharma—improving regulators, strengthening IP, and funding science—is a disruptive force. Operating at half the cost and three times the speed, China is on track to lead in multiple areas of drug discovery within 1-2 years.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

Pfizer's CEO argues the US is wasting resources trying to slow China's progress in pharma. He advocates shifting 80% of the effort to becoming better and faster domestically. This involves transforming US companies with technology and pushing for systemic changes in regulation, funding, and drug pricing.

China's biotech infrastructure enables companies to move from discovery to initial human proof-of-concept in under two years for less than $2 million per molecule. This rapid, low-cost development, particularly in new modalities like RNAi, presents a significant competitive threat that many Western innovators underestimate.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

In response to the competitive threat from Chinese firms operating at a different speed and cost, Pfizer's CEO states the only viable path forward is a radical transformation through technology, specifically citing AI. The goal is to fundamentally change processes to match the new competitive landscape.

The increasing innovation and speed from China puts pressure on the U.S. biotech ecosystem. To remain competitive, the U.S. must focus on collaboration and address its own systemic issues, such as slow trial execution and the high cost of getting a drug to the IND stage.

The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.